Sandoz Canada continues to expand generic product portfolio, The Canadian Business Journal

• Sand Canada recently launched ^{public relations}sand^®Apixaban SDZ and ^{public relations}sand^®Fesoterodine fumarate.
• ^{public relations}sand^®Apixaban SDZ is an important generic drug. The market for this product has grown over the last five years in Canada.
• Sandoz was the first manufacturer to launch a generic drug. ^{public relations}Tobias^®*(^{public relations}sand^®This helps bring significant savings to patients, hospitals and public and private drug insurance plan providers.

BOUCHEVILLE, Quebec, September 21, 2022 (GLOBE NEWSWIRE) — Sandoz Canada Inc. is proud to announce the launch of several products that expand its portfolio of high quality generic medicines.

^{public relations}sand^®Apixaban SDZ
^{public relations}sand^® Apixaban SDZ is one of our main products to be launched in 2022. ^{public relations}Oral antibiotics indicated for prevention of venous thromboembolism (VTE) in adults undergoing elective hip or knee replacement, stroke and systemic embolism in patients with atrial fibrillation, and treatment of deep veins. Coagulants Eliquis* thrombosis (DVT) and pulmonary embolism (PE) and prevention of their recurrence.

^{public relations}sand^® Apixaban SDZ is available in concentrations of 2.5 mg (bottle of 60 or 500 tablets) and 5 mg (blister pack of 60 tablets and bottle of 180 or 500 tablets).

Apixaban sales volume increased by more than 15% over the last 5 years¹, allowing us to actively contribute to the growing market. Being the most prescribed oral anticoagulant in Canada, ^{public relations}sand^® Apixaban SDZ could generate over $300 million in savings.² for the health system.

^{public relations}sand^®Fesoterodine fumarate
^{public relations}sand^® Fesoterodine fumarate is ^{public relations}Tobias^* Available in Canadian market. It is indicated for the symptomatic treatment of overactive bladder characterized by urinary frequency, urgency, incontinence, or any combination of these symptoms. He comes in two strengths of 4 mg or 8 mg and is available in bottles of 30 or 100 tablets respectively.

“We are proud to be a significant contributor to access to generic medicines in Canada. Sandoz Canada is dedicated to our role in the healthcare sector and our team is committed to expanding our product portfolio. We are constantly working to improve patient access to affordable, high-quality medicines.Our products generate significant savings that can be reinvested for the benefit of Canadians,” said Sand Michelle Robidoux, President and General Manager of Canada, said.

^® Trademarks owned or used by Sandoz Canada Inc. under license.
* Trademark owned by its registered owner.

Disclaimer

This press release contains forward-looking statements. ^{public relations}sand^® Apixaban SDZ and ^{public relations}sand^® Fesoterodine fumarate. Do not place undue reliance on these statements. These forward-looking statements reflect management’s current beliefs and expectations regarding future events and involve known and unknown risks and significant uncertainties. If one or more of these risks or uncertainties materializes, or if any of the underlying assumptions prove incorrect, actual results may differ from those set forth in the forward-looking statements. may differ significantly fromthere can be no guarantee that ^{public relations}sand^® Apixaban SDZ and ^{public relations}sand^® Fesoterodine fumarate may be submitted or approved for other additional indications or other market indications or at specific times. ^{public relations}sand^® apixaban SDZ, ^{public relations}sand^® Fesoterodine Fumarate is expected to be approved by regulatory agencies or become a commercial success in the future.In particular, management expectations regarding: ^{public relations}sand^® Apixaban SDZ and ^{public relations}sand^® Fesoterodine fumarate can be affected by many factors, including: Unexpected regulatory actions, delays, or government regulation in general. the company’s ability to obtain or maintain intellectual property protection; general economic and industry conditions; global trends towards rationalizing healthcare costs, including constant pressure on pricing; Impact of the COVID-19 pandemic. Unexpected manufacturing problems and other risks and factors described in Novartis AG’s Form 20-F filed with the US Securities and Exchange Commission. Sandoz is providing the information in this media release as of today and, except as required by law, Sandoz may not make any forward-looking statements herein as a result of new information, future events or otherwise. We do not undertake any obligation to update the description.

About sand
Sandoz International GmbH is a global leader in generics and biosimilars and a division of Swiss multinational Novartis.

Sandoz Canada is a pioneer in high-quality generic and biosimilar medicines serving more than 65 million prescriptions annually, based on decades of global experience and capabilities in product development, manufacturing and commercialization. , a leader and a reliable supplier. Sandoz launched its first biosimilars in Europe in 2006 and in the Canadian market in 2009.
www.sandoz.ca

Follow us on LinkedIn: https://www.linkedin.com/company/sandoz-canada/

contact:
Marie Soleil Pepin
Sando Canada Inc.
+1 438-227-2833
[email protected] / [email protected]

---

1 Data source: IQVIA CDH MAT June 2022
2 Data source: IQVIA CDH MAT June 2022

CBJ Newsmaker